Global Project Head, Efanesoctocog alfa (BIVV001), Rare Blood Disorders DevelopmentSanofi, Amsterdam, NetherlandsAmsterdam, Noord-Holland, Netherlands
PB1249 - Prospective, Observational Study of the Clinical Characteristics of Adults and Adolescents With Severe Hemophilia A
Tuesday, June 27, 202318:30 – 19:30 ET
OC 69.5 - Outcomes in Adult and Adolescent Patients With Severe Hemophilia A in the Phase 3 XTEND-1 Study Who Switched to Efanesoctocog Alfa Prophylaxis From an Observational Study With Factor VIII Prophylaxis
Wednesday, June 28, 202311:15 – 11:30 ET
